Biomerica, Inc. (BMRA) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Medical - Devices Branche. Der Hauptsitz des Unternehmens ist in Irvine, CA, United States. Der aktuelle CEO ist Zackary S. Irani.
BMRA hat IPO-Datum 1984-09-07, 64 Vollzeitbeschäftigte, gelistet an der NASDAQ Capital Marke, eine Marktkapitalisierung von $6.34M.
Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, or fecal specimens from patients in the diagnosis of various diseases and other medical complications; or to measure the level of specific bacteria, hormones, antibodies, antigens, or other substances, which exist in the patient's body and stools or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, diabetes, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods, an irritable bowel syndrome therapy technology and diagnostic-guided therapy; Helicobacter pylori products, as well as develops, tests, validates, and sells diagnostic products for COVID-19 infection. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.
